retatrutide triple agonist gip glp-1 glucagon Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Upcoming wave of hormone-based therapies
Description
This article reviews the mode of action for DPP-4 inhibitors and their application in the treatment of T2D
Master protocols to study multiple therapies, multiple diseases, or both
347 This was achieved by decreasing the expression of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-8 (IL-8)
Overall, 36 percent of employers are providing GLP-1 coverage for both diabetes and weight loss (up from 34 percent in 2024)
In addition to NAFLD, NASH is also of concern, with limited treatment options
Exercise consistency supports weight maintenance through multiple mechanisms
